Citations

Clear

904 citation(s) found for "Gordon, S".

Calcific Constrictive Pericarditis: Is It Still with Us?
Ling, Lieng Hsi , Oh, Jae K. , Breen, Jerome F., Danielson, Gordon K., Seward, James B., Tajik, A. Jamil , Schaff, Hartzell V. , Mahoney, Douglas W.

Mayo Clinic

Annals of Internal Medicine | April 12, 2013 | Volume: 132 | Issue: 6 | Pages: 444-450

10.7326/0003-4819-132-6-200003210-00004 | PMID 10733443 Get It

Ethical Issues in Stopping Randomized Trials Early Because of Apparent Benefit
Mueller, Paul S. , Bassler, Dirk , Koenig, Barbara A. , Montori, Víctor M. , Guyatt, Gordon

Mayo Clinic

Annals of Internal Medicine | April 12, 2013 | Volume: 146 | Issue: 12 | Pages: 878-881

10.7326/0003-4819-146-12-200706190-00009 | PMID 17577007 Get It

Primary CNS Posttransplant Lymphoproliferative Disease (PTLD): An International Report of 84 Cases in the Modern Era
Choquet, Sylvain , Jagadeesh, Deepa , Smith, Sonali M. , Leblond, V., Roy, Rupali, Gordon, Leo I. , Dierickx, Daan , Schiff, David , Evens, Andrew M. , Kroll‐Desrosiers, Aimee , Morschhauser, Franck , BARTON, BRUCE A. , Gandhi, Maher K. , Habermann, Thomas M. , Trappe, Ralf Ulrich , Gordon, Leo I

Mayo Clinic

American Journal of Transplantation | April 3, 2013 | Volume: No volume available | Issue: No issue available | Pages: n/a-n/a

10.1002/ajt.12211 Get It

Kit Signaling Is Required for Development of Coordinated Motility Patterns in Zebrafish Gastrointestinal Tract
Rich, Adam , Gordon, Scott M. , Gibbons, Simon J. , Schaefer, Katherine L. , Hennig, Grant W. , Farrugia, Gianrico , Brown, Christopher James , Gibbons, S J

Mayo Clinic

Zebrafish | January 8, 2013 | Volume: 10 | Issue: 2 | Pages: 154-160

10.1089/zeb.2012.0766 | PMID 23297728 Get It

Genetic polymorphisms associated with carotid artery intima-media thickness and coronary artery calcification in women of the Kronos Early Estrogen Prevention Study
Miller, Virginia M. , Petterson, Tanya M. , Jeavons, Elysia N, Lnu, Abhinita S., Rider, David N., Heit, John A. , Cunningham, Julie M. , Huggins, Gordon S. , Hodis, Howard N., Budoff, Matthew J. , Hopkins, Paul N. , Løbo, Rogerio A. , Taylor, Hugh S. , Harman, S. Mitchell , Santoro, Nanette F. , Manson, JoAnn E. , Naftolin, Frederick , Andrade, Mariza de , Budoff, Matthew

Mayo Clinic

Physiological Genomics | November 28, 2012 | Volume: 45 | Issue: 2 | Pages: 79-88

10.1152/physiolgenomics.00114.2012 | PMID 23188791 Get It

Menopausal hormone treatment (MHT) may limit progression of cardiovascular disease (CVD) but poses a thrombosis risk. To test targeted candidate gene variation for association with subclinical CVD defined by carotid artery intima-media thickness (CIMT) and coronary artery calcification (CAC), 610 women participating in the Kronos Early Estrogen Prevention Study (KEEPS), a clinical trial of MHT to prevent progression of CVD, were genotyped for 13,229 single nucleotide polymorphisms (SNPs) within 764 genes from anticoagulant, procoagulant, fibrinolytic, or innate immunity pathways. According to linear regression, proportion of European ancestry correlated negatively, but age at enrollment and pulse pressure correlated positively with CIMT. Adjusting for these variables, two SNPs, one on chromosome 2 for MAP4K4 gene (rs2236935, β = 0.037, P value = 2.36 × 10−06) and one on chromosome 5 for IL5 gene (rs739318, β = 0.051, P value = 5.02 × 10−05), associated positively with CIMT; two SNPs on chromosome 17 for CCL5 (rs4796119, β = −0.043, P value = 3.59 × 10−05; rs2291299, β = −0.032, P value = 5.59 × 10−05) correlated negatively with CIMT; only rs2236935 remained significant after correcting for multiple testing. Using logistic regression, when we adjusted for waist circumference, two SNPs (rs11465886, IRAK2, chromosome 3, OR = 3.91, P value = 1.10 × 10−04; and rs17751769, SERPINA1, chromosome 14, OR = 1.96, P value = 2.42 × 10−04) associated positively with a CAC score of >0 Agatston unit; one SNP (rs630014, ABO, OR = 0.51, P value = 2.51 × 10−04) associated negatively; none remained significant after correcting for multiple testing. Whether these SNPs associate with CIMT and CAC in women randomized to MHT remains to be determined.
The American Congress of Physical Medicine and Rehabilitation: Annual Session, 1955
Martin, Gordon M.

Mayo Clinic

Rheumatology | November 20, 2012 | Volume: 3 | Issue: 2 | Pages: 61-63

10.1093/rheumatology/iii.2.61 Get It

The Dangers of Stopping a Trial Too Early
Briel, Matthias , Bassler, Dirk , Wang, Amy T. , Montori, Víctor M. , Guyatt, Gordon , Montori, Victor M

Mayo Clinic

Journal of Bone and Joint Surgery | November 15, 2012 | Volume: 94 | Issue: Supplement_1 | Pages: 56-60

10.2106/jbjs.k.01412 | PMID 22810449 Get It

Abstract: To ensure that participants in randomized controlled trials are protected from harm, interim analyses and review of results by an independent data monitoring committee have become standard practice. If an analysis of accumulating data partway through a trial reveals an unanticipated degree of benefit or toxicity, or differences in outcomes between the intervention and control groups are so unimpressive that any prospect of a positive result with the planned sample size is extremely unlikely, investigators may stop the trial earlier than originally scheduled. The practice of stopping randomized controlled trials early is, however, problematic, especially if the trial is stopped for apparent benefit. Concerns in trials stopped early for apparent benefit include appropriate interpretation of results and ethical problems concerning trial participants, clinicians, and society as a whole. In this article, we review the epidemiology of trials stopped early and illustrate some of the problems and controversies associated with stopping randomized controlled trials early for apparent benefit. Finally, we offer guidance for clinicians, those running clinical trials, and authors of systematic reviews.
Use and Interpretation of Composite End Points in Orthopaedic Trials
Busse, Jason W. , Bhandari, Mohit , Ferreira‐González, Ignacio , Montori, Víctor M. , Guyatt, Gordon , Montori, Victor M

Mayo Clinic

Journal of Bone and Joint Surgery | November 15, 2012 | Volume: 94 | Issue: Supplement_1 | Pages: 65-69

10.2106/jbjs.k.01287 | PMID 22810451 Get It

Abstract: Randomized controlled trials in orthopaedics are often underpowered to detect important differences in outcomes. Composite end points (CEPs) hold promise as a strategy to address this issue by combining multiple end points into one summary measure, thus increasing the observed event rate. The use of CEPs by trialists, however, can be problematic when they include components that vary greatly in importance to patients and when differences in apparent effect between components are large. We present an overview of CEPs with a focus on appropriate design and interpretation of results.